Lazarus Michael B, Novotny Chris J, Shokat Kevan M
Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco , San Francisco, California 94158, United States.
ACS Chem Biol. 2015 Jan 16;10(1):257-61. doi: 10.1021/cb500835z. Epub 2015 Jan 6.
Autophagy is a conserved cellular process that involves the degradation of cellular components for energy maintenance and cytoplasmic quality control that has recently gained interest as a novel target for a variety of human diseases, including cancer. A prime candidate to determine the potential therapeutic benefit of targeting autophagy is the kinase ULK1, whose activation initiates autophagy. Here, we report the first structures of ULK1, in complex with multiple potent inhibitors. These structures show features unique to the enzyme and will provide a path for the rational design of selective compounds as cellular probes and potential therapeutics.
自噬是一种保守的细胞过程,涉及细胞成分的降解以维持能量和进行细胞质质量控制,最近作为包括癌症在内的多种人类疾病的新靶点而受到关注。确定靶向自噬潜在治疗益处的一个主要候选者是激酶ULK1,其激活启动自噬。在此,我们报道了ULK1与多种强效抑制剂复合物的首个结构。这些结构显示了该酶独特的特征,并将为合理设计选择性化合物作为细胞探针和潜在治疗药物提供途径。